NICE has recommended AbbVie’s Elahere (mirvetuximab soravtansine) for FRα‑positive platinum‑resistant ovarian cancer, the first new NHS‑funded therapy in over 20 years, delivering survival gains and quality‑of‑life benefits.
Written By: Kirti Kumbhar, M. Pharm (QA)
Reviewed By: Pharmacally Editorial Team
The UK’s National Institute for Health and Care Excellence (NICE) has recommended AbbVie’s mirvetuximab soravtansine-gynx (Elahere) for adults with folate receptor alpha (FRα)-positive platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer.
NICE’s recommendation introduces the first new NHS-funded treatment option in more than 20 years for women with this form of ovarian cancer, a setting where therapeutic advances have been limited and treatment options remain scarce.
Patient Eligibility and Access
The guidance applies to patients whose tumors express FRα and who have received one to three prior systemic therapies. Eligible patients in England will gain immediate access through the NHS Cancer Drugs Fund, with routine commissioning to follow publication of final guidance.
Approximately 270 patients are expected to benefit during the first year, rising to around 420 by year three as access to FRα diagnostic testing becomes more widely available.
Targeted ADC Approach
Mirvetuximab soravtansine is an antibody-drug conjugate (ADC) that combines a monoclonal antibody targeting FRα with a potent cytotoxic payload. By binding to FRα-expressing tumor cells, the therapy delivers its cancer-killing agent directly into malignant cells while limiting exposure to healthy tissue.
FRα is highly expressed in many ovarian cancers, making it an attractive therapeutic target. Platinum-resistant ovarian cancer develops when the disease progresses within six months of platinum-based chemotherapy and is associated with poor outcomes, limited treatment options, and substantial treatment burden.
Clinical Evidence from MIRASOL
NICE’s recommendation was supported by results from the pivotal Phase 3 MIRASOL trial (NCT04209855), which enrolled 453 adults with FRα-positive platinum-resistant ovarian cancer.
Patients treated with Elahere achieved a median overall survival of 16.9 months compared with 13.0 months for those receiving investigator’s choice chemotherapy. The therapy also improved progression-free survival, delaying disease progression to 5.6 months versus 4.0 months with chemotherapy.
The findings demonstrated clinically meaningful improvements in both survival outcomes and disease control for a patient population with historically limited therapeutic options.
Quality-of-Life Gains
Beyond efficacy, patient and clinician feedback highlighted significant quality-of-life benefits. Conventional chemotherapy often requires frequent hospital visits and can cause fatigue, hair loss, nausea, and neuropathy that substantially affect daily life.
By contrast, Elahere is administered once every three weeks and was associated with a more manageable treatment experience and fewer treatment-related disruptions to everyday activities. Patients reported greater ability to maintain work, social engagement, and independence during treatment.
Regulatory and Commercial Context
Helen Knight, Director of Medicines Evaluation at NICE, emphasized the committee’s recognition of the limited options available to women with platinum-resistant ovarian cancer and the significant burden associated with chemotherapy.
Following a confidential commercial agreement between AbbVie and NHS England, NICE concluded that Elahere represents a cost-effective use of NHS resources for this high-need patient population. The recommendation builds on AbbVie’s broader regulatory progress for the therapy, including its approval in the United States for FRα-positive platinum-resistant ovarian cancer.
Changing the Standard of Care
The recommendation expands NHS access to a treatment that improves survival while reducing treatment burden for women with platinum-resistant ovarian cancer. For a patient population that has seen few therapeutic advances over the past two decades, the decision represents an important shift in care.
NICE’s endorsement also reinforces the growing role of antibody-drug conjugates in ovarian cancer treatment and highlights the continued expansion of precision oncology approaches across solid tumors.
Reference
First new NHS treatment in over 20 years recommended for women with resistant ovarian cancer | NICE
About the Writer
Kirti Kumbhar (LinkedIn) is an M.Pharm graduate with experience in Quality Assurance at Lupin Limited and a strong interest in clinical research, regulatory affairs, and Trial Master File (TMF) management. She has developed knowledge of regulatory documentation, quality systems, compliance, and healthcare research through her professional experience. Passionate about clinical development and continuous learning, Kirti is committed to supporting high-quality healthcare documentation, regulatory excellence, and research-driven healthcare advancements.